Isomorphic Labs

Investor: Alphabet

Isomorphic Labs, a London-based AI drug discovery firm spun out of Google DeepMind, is reportedly in early-stage discussions to secure fresh funding at a valuation of up to $50 billion. This potential raise follows a major $2.1 billion Series B round completed in May, alongside a $600 million raise in March 2025.Summary of transaction details:Value: $2.1 billion (Series B) / Target Valuation up to $50 billionSector: Healthcare & BiotechAdvisor: NoneKey Entities: Isomorphic Labs, Alphabet, Thrive Capital, UK Sovereign AI FundLocation: London, United KingdomNote: Led by Nobel laureate Sir Demis Hassabis, Isomorphic Labs leverages AlphaFold technology to predict how molecules interact with biological targets. While the firm has attracted massive investor interest, its AI-discovered treatments have yet to enter human clinical trials, which are currently slated to begin by the end of 2026.

Isomorphic Labs, an Artificial Intelligence firm, completed a substantial funding round valued at approximately £1.6 billion ($2.1 billion) in the first half of 2026. This transaction stands out as the largest of four AI deals exceeding $1 billion during the period, highlighting significant investor interest in the sector. Summary of transaction details: Value: £1.6 billion ($2.1 billion) Sector: DeepTech & AI Advisor: Not mentioned Key Entities: Isomorphic Labs (Target) Location: UK (implied by "UK start-ups raised...") Note: This funding round exemplifies the substantial capital inflow into late-stage AI companies within the UK, driving record venture capital investment for the first half of 2026 and reflecting growing confidence in the nation's innovation ecosystem.

Isomorphic Labs, a pioneering company in AI-driven drug discovery, successfully raised £1.6 billion ($2.1 billion) in a significant funding round during the first half of 2026, contributing to a record period for UK startup investment.Summary of transaction details:Value: £1.6 Billion ($2.1 Billion)Sector: Healthcare & BiotechAdvisor: Not disclosedKey Entities: Target: Isomorphic Labs; Investor: Not disclosedLocation: United Kingdom (as part of UK funding trends)Note: This transaction exemplifies the strong investor appetite for deep tech and AI innovations, particularly within the life sciences sector, reinforcing the UK's growing prominence in the global venture capital landscape.

Investor: Thrive Capital

London-based Isomorphic Labs, the AI-first drug discovery company spun out of Google DeepMind, has secured a historic £1.6 billion ($2.1 billion) Series B funding round led by Thrive Capital. Summary of transaction details: Value: £1.6 billion ($2.1 billion) Sector: Healthcare & Biotech / MedTech Advisor: Not disclosed Key Entities: Target: Isomorphic Labs; Lead Investor: Thrive Capital; Participating Investors: Alphabet, GV, MGX, Temasek, CapitalG, and the UK Sovereign AI Fund Location: London, UK Note: Founded by Sir Demis Hassabis, Isomorphic Labs is on a mission to "solve all disease" by transitioning from pioneering AI models to applying them at industrial scale. This capital injection focuses on the deployment of IsoDDE, the firm's proprietary AI drug design engine. The platform has already hit key milestones across internal programs with "unprecedented speed" and supports major strategic partnerships with industry titans including Novartis, Eli Lilly, and Johnson & Johnson. The funding follows a £462.3 million raise in April 2025 and will be used to accelerate therapeutic pipelines toward clinical trials while scaling global hiring for AI, engineering, and clinical talent.

Investor: Thrive Capital

Isomorphic Labs, a prominent spinout from Google DeepMind specializing in AI-driven drug discovery technology, has successfully secured $600 million (£464.6 million) in its inaugural external funding round.Summary of transaction details:Value: £464.6 millionSector: Healthcare & Biotech, DeepTech & AIAdvisor: None mentionedKey Entities: Target: Isomorphic Labs; Lead Investor: Thrive Capital; Additional Investors: Alphabet, Google VenturesLocation: UK-affiliatedNote: This substantial investment underscores the increasing strategic importance and high growth potential of artificial intelligence applications in revolutionizing pharmaceutical research and development, positioning Isomorphic Labs as a key player in the future of drug design.

Investor: Thrive Capital, Alphabet, GV, MGX, Temasek, CapitalG, UK Sovereign AI Fund

Isomorphic Labs, a London-based company leveraging artificial intelligence for drug discovery, has successfully closed a Series B funding round, raising £1.6 billion.Summary of transaction details:Value: £1.6 billionSector: Healthcare & BiotechAdvisor: Not specifiedKey Entities: Isomorphic Labs (Target), Thrive Capital, Alphabet, GV, MGX, Temasek, CapitalG, UK Sovereign AI Fund (Investors)Location: London (Target HQ)Note: This substantial investment underscores the increasing strategic importance and commercial viability of AI applications in accelerating and enhancing the drug discovery process within the pharmaceutical industry.